{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-021120","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.972435+00:00","generated_at":"2026-05-15T23:06:56.774814+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INmune Bio pipeline update: CORDStrom Phase 3 data and XPro1595 FDA alignment for Phase 2b/3 AD trial","bullets":["CORDStrom Phase 3 shows improvements in itch, pain, and skin scores in RDEB; MAA submission expected Q3 2026 for UK.","XPro1595 Phase 2 MINDFuL trial met FDA end-of-Phase 2 meeting; adaptive Phase 2b/3 design with CDR-SB primary accepted.","CORDStrom potential TAM >$1.4B; annual COG $120-180K; anticipated reimbursement ~$700K per year.","XPro1595 showed zero ARIA events in high-risk APOE4+ population; Phase 3 readiness targeted for 2027.","CORDStrom regulatory milestones: RPDD and ODD approved, pre-MAA doc submitted, BLA/MAA submissions planned in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-021120","json":"https://secwatch.observer/filing/0001213900-26-021120.json","markdown":"https://secwatch.observer/filing/0001213900-26-021120.md","text":"https://secwatch.observer/filing/0001213900-26-021120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026021120/0001213900-26-021120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026021120/ea02262026-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:06:56.774814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}